诺和诺德面临挑战：资本市场日揭示增长预期瓶颈
· gurufocus.com
诺和诺德（NVO）在资本市场日后股价大幅下跌，其2026年至2030年的营收增长预测仅符合现有共识，投资者原本期待上调预期，结果大失所望。
Novo Nordisk NVO has experienced a significant decline following its Capital Markets Day, where it projected revenue growth from 2026 to 2030 that aligns with t...